Physician profile
Myra Hale
NPI 1255789889
$876.80
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.67 · 2021: $697 · 2022: $168.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $373.51 | 2021-2022 | |
| Abbvie INC. | $245.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $66.01 | 2022 | |
| Esperion Therapeutics, INC. | $39.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.71 | 2021 | |
| Lilly USA, LLC | $18.38 | 2021 | |
| Amgen INC. | $17.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.76 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.67 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.19 | 2021 | |
| Allergan, INC. | $12.18 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myra Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.